登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式(希尔记法):
C24H26N2O4
化学文摘社编号:
分子量:
406.47
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
solid
产品名称
卡维地洛, ≥98% (HPLC), solid
Quality Segment
assay
≥98% (HPLC)
form
solid
color
white to off-white
solubility
DMSO: >20 mg/mL
originator
GlaxoSmithKline
SMILES string
OC(COC1=CC=CC2=C1C3=C(C=CC=C3)N2)CNCCOC4=CC=CC=C4OC
InChI
1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3
InChI key
OGHNVEJMJSYVRP-UHFFFAOYSA-N
Gene Information
human ... ADRA1A(148), ADRA1B(147), ADRA1D(146), ADRB1(153), ADRB2(154), ADRB3(155)
Application
Carvedilol has been used:
- as a β blocker to determine its effect on hypoxia inducible factor (HIF)-mediated erythropoiesis under hypoxia in vivo
- as a βAR antagonist for inhibition of bARs
- as a β-blocker to examine airway mechanics in fungus-challenged mice
Biochem/physiol Actions
Cavedilol is a non-selective β-adrenergic blocker with α1 blocking activity. Carvedilol is used specifically for the treatment of heart failure and high blood pressure. It has been shown to improve left ventricular ejection fraction and may reduce mortality.
Cavedilol is a non-selective β-adrenergic blocker with α1 blocking activity.
Features and Benefits
This compound is featured on the β-Adrenoceptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Still not finding the right product?
Explore all of our products under 卡维地洛
signalword
Warning
hcodes
Hazard Classifications
Aquatic Chronic 2 - STOT RE 2
target_organs
Liver,spleen,Uterus (including cervix),Adrenal gland
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves

